Synthaverse

Synthaverse Current Liabilities

The Current Liabilities of Synthaverse (SVE.WA) as of Oct 17, 2026 is 134.06 M PLN. In the previous year, Current Liabilities was 60.23 M PLN — a change of 122.59% (higher).

Current Liabilities

134.06 MPLN

YoY

122.59%

Last updated:

Current Liabilities of Synthaverse is 2025 134.06 M PLN. Current Liabilities of Synthaverse was 2024 60.23 M PLN. It decreases by 122.59% higher compared to the previous year.

The Synthaverse Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
32.67 M PLN
Jan 1, 2019
7.90 M PLN
Jan 1, 2020
18.15 M PLN
Jan 1, 2021
11.64 M PLN
Jan 1, 2022
16.53 M PLN
Jan 1, 2023
43.86 M PLN
Jan 1, 2024
60.23 M PLN
Jan 1, 2025
134.06 M PLN
The Synthaverse Current Liabilities history
YEARCurrent LiabilitiesYoY
134.06 MPLN+122.59%
60.23 MPLN+37.32%
43.86 MPLN+165.42%
16.53 MPLN+41.99%
11.64 MPLN-35.88%
18.15 MPLN+129.88%
7.90 MPLN-75.84%
32.67 MPLN+7.31%
30.45 MPLN-65.98%
89.50 MPLN-29.13%
126.28 MPLN+237.73%
37.39 MPLN+67.37%
22.34 MPLN-35.48%
34.63 MPLN+21.93%
28.40 MPLN+3.36%
27.48 MPLN-12.93%
31.56 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Synthaverse Stock analysis

What does Synthaverse do? Biomed Lublin is a Polish company that has been active in the production of serums and vaccines since 1950. It has grown to become a leading producer of biological substances and medical devices in Eastern Europe. The company was originally a state institution for the development of animal vaccines but was privatized after the political changes in the late 1980s. Since 2002, it has been listed on the Warsaw Stock Exchange and has expanded its focus. Biomed Lublin operates in four main areas: veterinary medicine, human medicine, diagnostics, and laboratory equipment. It has a strong reputation in the veterinary medicine field, offering vaccines and diagnostics for livestock and pets. The company is also involved in human medicine, producing vaccines and diagnostics exclusively in Poland. In the diagnostics field, Biomed Lublin has developed and manufactured a variety of test kits used in medical diagnostics. It also offers laboratory equipment such as microscopes, pipettes, and centrifuges for medical and biological testing in hospitals and laboratories. Overall, Biomed Lublin aims to continue expanding its presence in the biotech industry in Eastern Europe and providing high-quality and effective diagnostic and therapeutic solutions to improve the health of both humans and animals. Synthaverse is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Synthaverse stock

Current Liabilities of Synthaverse is 134.06 M PLN in 2025.

Current Liabilities of Synthaverse changed from 60.23 M PLN to 134.06 M PLN, representing a 122.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Synthaverse since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Synthaverse historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Synthaverse

All Key Metrics — Synthaverse